{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:17:29Z","timestamp":1753881449891,"version":"3.41.2"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>\n            Solithromycin (CEM-101) is a novel fluoroketolide antimicrobial agent with activity against typical and atypical pathogens associated with community-acquired bacterial pneumonia. Using a neutropenic murine lung infection model, the objectives of this study were to identify the pharmacokinetic\/pharmacodynamic (PK\/PD) index most closely associated with efficacy and the magnitude of such indices associated with solithromycin efficacy against\n            <jats:named-content content-type=\"genus-species\">Streptococcus pneumoniae<\/jats:named-content>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.02606-18","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T14:18:42Z","timestamp":1560176322000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetic\/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model"],"prefix":"10.1128","volume":"63","author":[{"given":"Olanrewaju O.","family":"Okusanya","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Forrest","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhavathi","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Cempra Pharmaceuticals, Inc., Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Andes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases, University of Wisconsin School of Medicine, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00185-16"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01639-13"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01343-09"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00090-09"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.03.2130"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.129502"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00941-16"},{"key":"e_1_3_3_9_2","volume-title":"Abstr 113th Annual Conference of the American Thoracic Society","author":"Flamm RK","year":"2017","unstructured":"Flamm RK, Steenbergen JN, Huband MD, Rhomberg PR, Sader HS. Activity of omadacycline when tested against respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus isolated during 2016 from medical centers in the USA, abstr 5989. 2017. Abstr 113th Annual Conference of the American Thoracic Society, Washington, DC."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01555-17"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00017-7"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw490"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/9781420017137.001"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3944-3947.2005"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.13-22.2001"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00985-09"},{"key":"e_1_3_3_17_2","volume-title":"Abstr 47th Intersci Conf Antimicrob Agents Chemother","author":"Bhavnani SM","year":"2007","unstructured":"Bhavnani SM, Rubino CM, Forrest A, Lehoux D, Okusanya OO, Drusano GL, Rodvold KA, Craig WA, Ambrose PG, Parr TJ, Jr. 2007. Use of PK\/PD principles to guide clinical drug development for oritavancin, abstr A-51. Abstr 47th Intersci Conf Antimicrob Agents Chemother, Chicago, IL."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02404-18"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00211-17"},{"key":"e_1_3_3_20_2","volume-title":"Ketek (telithromycin) package insert","author":"Sanofi-Aventis, U.S., LLC","year":"2015","unstructured":"Sanofi-Aventis, U.S., LLC. 2015. Ketek (telithromycin) package insert. Bridgewater, NJ."},{"key":"e_1_3_3_21_2","volume-title":"Abstr 42nd Intersci Conf Antimicrob Agents Chemother","author":"Craig WA","year":"2002","unstructured":"Craig WA, Kiem S, Andes DR. 2002. Free-drug 24-hr AUC\/MIC is the PK\/PD target that correlates with in vivo efficacy of macrolides, azilides, ketolides and clindamycin, abstr A-1264. Abstr 42nd Intersci Conf Antimicrob Agents Chemother, San Diego, CA."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.12.005"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-12"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00133-06"},{"key":"e_1_3_3_25_2","first-page":"37","article-title":"Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: Contribution of intestinal first-pass effect to low bioavailability","volume":"10","author":"Lee JH","year":"2007","unstructured":"Lee JH, Lee MG. 2007. Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: Contribution of intestinal first-pass effect to low bioavailability. J Pharm Pharmaceut Sci 10:37\u201350.","journal-title":"J Pharm Pharmaceut Sci"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.411"},{"key":"e_1_3_3_27_2","volume-title":"Draft guidance","author":"United States Department of Health and Human Services, Food and Drug Administration","year":"2014","unstructured":"United States Department of Health and Human Services, Food and Drug Administration. 2014. Guidance for Industry. Community-acquired bacterial pneumonia: Developing drugs for treatment. Draft guidance. United States Food and Drug Administration, Silver Spring, MD."},{"key":"e_1_3_3_28_2","volume-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products","author":"European Medicines Agency, Committee for Medicinal Products for Human Use","year":"2016","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. 2016. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. European Medicines Agency, Amsterdam, Netherlands."},{"key":"e_1_3_3_29_2","volume-title":"Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2009","unstructured":"Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, approved standard 8th ed. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"8"},{"key":"e_1_3_3_30_2","volume-title":"Performance standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for Antimicrobial Susceptibility Testing, 29th ed. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"29"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1986.60.2.532"},{"key":"e_1_3_3_32_2","volume-title":"S-ADAPT\/MCPEM user\u2019s guide: software for pharmacokinetic, pharmacodynamic and population data analysis","author":"Bauer RJ","year":"2008","unstructured":"Bauer RJ. 2008. S-ADAPT\/MCPEM user\u2019s guide: software for pharmacokinetic, pharmacodynamic and population data analysis, version 1.56. Berkley, CA."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.2307\/2335654"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.243-249.2006"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"volume-title":"Abstr 50th Intersci Conf Antimicrob Agents Chemother","author":"Okusanya OO","key":"e_1_3_3_36_2","unstructured":"Okusanya OO, Bhavnani SM, Forrest A, Fernandes P, Ambrose PG. Pharmacokinetic-pharmacodynamic target attainment analysis supporting CEM-101 phase 2 dose selection, abstr A1-692. Abstr 50th Intersci Conf Antimicrob Agents Chemother, Boston, MA."},{"volume-title":"Abstr 52nd Intersci Conf Antimicrob Agents Chemother","author":"Okusanya OO","key":"e_1_3_3_37_2","unstructured":"Okusanya OO, Bhavnani SM, Forrest A, Bulik CC, Oldach D, Fernandes P, Ambrose PG. Population pharmacokinetic and pharmacokinetic-pharmacodynamic target attainment analyses for solithromycin to support intravenous dose selection in patients with community-acquired bacterial pneumonia, abstr A-1269. Abstr 52nd Intersci Conf Antimicrob Agents Chemother, San Francisco, CA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02606-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02606-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:29:53Z","timestamp":1645478993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02606-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1128\/AAC.02606-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02606-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"2018-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02606-18"}}